贝美前列素滴眼液上市后对预算影响的初步分析.docxVIP

·药物经济学·贝美前列素滴眼液上市后对预算影响的初步分析杨兴华1* ，中国医师协会药物经济学评价中心2 (1. 首都 ·药物经济学· 贝美前列素滴眼液上市后对预算影响的初步分析 杨兴华1* ，中国医师协会药物经济学评价中心2 (1. 首都医科大学，北京 100069;2. 中国医师协会药物经济学 评价中心，北京 中图分类号 R956 100029) 文献标识码 B 文章编号 1672 － 2124(2010)11 － 1015 － 04 摘 要 目的:对贝美前列素滴眼液对比同类药物拉坦前列素进行预算影响的初步分析。方法:应用预算影响分析方法对贝美 前列素滴眼液上市后未来 5 年的可能费用与对照药物对比，得出增量情况。结果:按 10% 市场占有率情况下，2 种药物费用增量 为 － 16 000万元，从不同地区的预算影响分析贝美前列素的治疗成本要低于拉坦前列素，年费用相差在 300 ～ 400 万元。结论:按 假定情况，贝美前列素引入医保目录后与拉坦前列素相比年节约药品费用在 16 000 万元及以上;预测影响分析结果受不同地域 社会发展状况、经济环境和医疗卫生状况影响，按不同地区分层进行预算影响分析是必要的。 贝美前列素滴眼液;预算影响;初步分析 关键词 Budget Impact Analysis on Bimatoprost Ophthalmic Solution after Its Introduction into the Market YANG Xing-hua1* ，Centre of Pharmacoeconomics Evaluation of Chinese Medical Doctor Association2 (1. Capital Medical University，Beijing 100069，China;2. Centre of Pharmacoeconomics Evaluation of Chinese Medical Doctor Association，Beijing 100027，China) OBJECTIVE: To perform a pilot budget impact analysis on Bimatoprost Ophthalmic Solution with ABSTRACT Latanoprost as control. METHODS: Budget impact analysis was employed to analyze the increament of the possible costs of Bimatoprost Ophthalmic Solution vs. Latanoprost in future 5 years after its introduction into the market. RESULTS: If with a market share of 10% ，the cost increment of Ophthalmic Solution vs. Latanoprost were － 160 million Yuan. The budget impact analysis on Bimatoprost Ophthalmic Solution vs. Latanoprost in different district showed a lower treatment cost of bimatoprost than that of Latanoprost，with annual cost difference of 3-4 millions. CONCLUSION: Based on presumed condition，an annual drug cost saving of 160 million Yuan is possible if enlisting Bimatoprost Ophthalmic Solution as medical care list drugs as compared with Latanoprost. The predicated impact analysis results were influenced by social development condition，economical，medical and health conditions in different regions，thus it is necessary to con